8-Bromo-3-methyl-7-but-2-ynyl xanthine 99%
Price | Get Latest Price | ||||
Packge | 1MT | 1kg | 5kg | 10kg | 25kg |
- Min. Order:1MT
- Time:2024-01-12
Product Details
- Product Name8-Bromo-3-methyl-7-but-2-ynyl xanthine
- CAS No.666816-98-4
- EINECS No.613-975-8
- MFC10H9BrN4O2
- MW297.11
- Appearancepowder to crystalWhite to Almost white
- density 1.71
- Melting point 285 °C
- storage temp. 2-8°C
Company Profile Introduction
Neoloba Specialty Private Limited is an unlisted private company incorporated on 17 January, 2015. It is classified as a private limited company and is located in Thane, Maharashtra. It's authorized share capital is INR 50.00 lac and the total paid-up capital is INR 41.00 lac.
Neoloba Specialty Private Limited's operating revenues range is INR 1 cr - 100 cr for the financial year ending on 31 March, 2023. It's EBITDA has increased by 23.58 % over the previous year. At the same time, it's book networth has increased by 13.24 %.
Supplier other products
Recommended supplier
-
VIP1年
- Scimplify
- 666816-98-4 99%
- Inquiry
- 2024-10-25
-
VIP1年
- Mekanar Pharma Private Limited
- 666816-98-4 99%
- Inquiry
- 2024-05-22
-
VIP1年
- ADAARSH PHARMA
- 666816-98-4 99%
- Inquiry
- 2024-05-03
-
VIP1年
- Bakul Pharma Private Limited
- 8-Bromo-3-methyl-7-but-2-ynyl xanthine 99%
- Inquiry
- 2024-03-07
-
VIP1年
- Kores India Limited (Kores Pharmaceuticals And Chemicals)
- 666816-98-4 98%
- Inquiry
- 2024-02-29
-
VIP1年
- Arnavi Laboratory
- 666816-98-4 8-Bromo-3-methyl-7-but-2-ynyl xanthine 98%
- Inquiry
- 2024-02-20
-
VIP1年
- Ralington Pharma
- 8-Bromo-3-methyl-7-but-2-ynyl xanthine 666816-98-4 98%
- Inquiry
- 2024-02-05
-
VIP1年
- Maitree Research Pvt Ltd
- 8-Bromo-3-methyl-7-but-2-ynyl xanthine 99%
- Inquiry
- 2024-02-01
-
VIP1年
- Raghava Life Sciences
- 666816-98-4 98%
- Inquiry
- 2024-01-24
-
VIP0年
- JISAI
- 666816-98-4 8-Bromo-3-methyl-7-but-2-ynyl xanthine 98%
- Inquiry
- 2024-01-24
- Since:2020-01-01
- Address: Plot no. A-19, A-19 (Part) & C-10/1, MIDC Phase-1, Dombivali East, Dist., Thane, Maharashtra-421203,
INQUIRY